RxDoctor Payments Data

James Partridge, MD

Internal Medicine · Durham, NCNPI 1629015227

Payments from drug & device makers

$2,137in general payments, 2019–2025

Across 127 payments — averaging $16.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$446
  • Novo Nordisk$368
  • Boehringer Ingelheim$216
  • Dexcom, Inc.$117
  • Pfizer$108
  • Astellas Pharma US Inc$101
  • plus $781 from 17 others

What the payments were for

  • Food & beverage$2,11499%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,137 in reported general payments places this provider in the 80th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$67,427
Medicare patients
141
Services billed
1,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$91,969
EliquisApixaban89$87,738
JardianceEmpagliflozin61$80,282
Janumet XrSitagliptin Phos/Metformin Hcl68$74,869
FarxigaDapagliflozin Propanediol46$48,760
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,767
MounjaroTirzepatide18$22,945
Repatha SureclickEvolocumab21$15,284
EntrestoSacubitril/Valsartan12$14,631
ShingrixVaricella-Zoster Ge/As01b/Pf62$13,687
XareltoRivaroxaban12$11,304
ArexvyRsvpref3 Antigen/As01e/Pf34$10,889
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$10,875
MyrbetriqMirabegron11$9,354
Rosuvastatin Calcium461$5,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$368$91,96969 claims
PfizerEliquis$108$87,73889 claims
Boehringer IngelheimJardiance$216$80,28261 claims
MerckJanumet Xr$75$74,86968 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$62$54,343132 claims
AstraZenecaFarxiga$55$48,76046 claims
Lilly USA, LLCMounjaro$446$22,94518 claims
Johnson & JohnsonXarelto$29$11,30412 claims
Astellas Pharma US IncMyrbetriq$101$9,35411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →